摘要
Small-cell lung cancer(SCLC)accounts for 15%–20%of primary lung cancers,and it is characterized by low differentiation,rapid proliferation,and early metastasis.At least two-thirds of SCLC patients present with the extensive stage(ES)at the time of initial clinical diagnosis.Over the last 2 decades,platinum-based combination chemotherapy has remained the standard first-line treatment for SCLC.With the introduction of the immunotherapy era,immunotherapy plus chemotherapy has replaced conventional chemotherapy as the first-line treatment option for ES-SCLC and is recommended by National Comprehensive Cancer Network clinical guidelines.Therefore,in this review,we present the latest research advances in SCLC treatment,predictive biomarkers,and other topics of high interest to provide options for patients with SCLC.
基金
Taishan Scholar Foundation of Shandong Province,Grant/Award Number:tsqn202103179
National Natural Science Foundation of China,Grant/Award Number:81802284
Science and Technology Development Plans of Shandong Province,Grant/Award Number:2014GSF118157
Scientific Research Foundation of Shandong Province of Outstanding Young Scientists,Grant/Award Number:BS2013YY058
2021 Shandong Medical Association Clinical Research Fund,Grant/Award Number:YXH2022ZX02176。